This session examines Saudi Arabia’s value proposition as a regional manufacturing hub for healthcare and medical ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The biotech industry has pushed the boundaries of human health and scientific understanding for decades. But a new revolution is brewing—not in the lab, but in the supply chain. By embracing ...

Scientific breakthroughs will enable a future of personalized drug discovery, where precision medicine makes it possible to receive the right dose of the right medicine at the right time. America’s ...

Biotech stocks have been on the rise since news outlets reported that President Donald Trump’s executive order tackling drug prices will contain industry-friendly policies, according to Bloomberg ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

PharmTech spoke with Dexter Tjoa, CEO of Tjoapack, about how outside pressures are influencing supply chain and packaging ...

Industry wants policy intervention through technology upgradation, quality infra and R&D in Budget 2026: Shardul Nautiyal, Mumbai Saturday, January 24, 2026, 08:00 Hrs [IST] As we ...

On the surface, biotechnology and value do not have much in common. Biotech companies lack predictable cash flows and calculable margins of safety; the sector is one of the market’s most volatile.

POMDOCTOR LIMITED ('Pomdoctor' or the 'Company') (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced significant progress in its strategic ...